Literature DB >> 9535131

Cerebellar neurodegeneration in human hereditary DNA repair disorders.

T Kohji1, M Hayashi, K Shioda, M Minagawa, Y Morimatsu, K Tamagawa, M Oda.   

Abstract

Recent findings have focused attention on the role of apoptosis in neurodegenerative diseases, however, the apoptotic process in child-onset brain disorders has been little investigated. Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are hereditary disorders characterized by impaired DNA repair and neurodegeneration. We investigated apoptotic cell death in the cerebellum of five cases of XP group A (XPA), four cases of CS, and twelve controls, using TdT-mediated DIG-dUTP nick-end labeling (TUNEL) and immunohistochemical staining for bcl-2, bcl-x, p53, bax, BDNF and Trk B. The TUNEL-positive cells were found in the granule cells of the cerebellar cortex of two patients with XPA and two patients with CS, whereas such cells were not detected in the cerebellar cortex in controls. Upregulation of bcl-2 or BDNF was not observed, and bcl-x expression was not altered. Some patients showed nuclear expression of p53 in the granule cells and/or molecular layer, bax-positive glial cells in the cerebellar white matter, and a few Trk B-positive cells in the granular layer. These findings suggest that apoptotic cell death can be involved in the cerebellar degeneration in patients with hereditary defects in DNA repair mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535131     DOI: 10.1016/s0304-3940(98)00109-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

Review 1.  p53-dependent cell death signaling in neurons.

Authors:  Richard S Morrison; Yoshito Kinoshita; Mark D Johnson; Weiqun Guo; Gwenn A Garden
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

2.  Increased apoptosis, p53 up-regulation, and cerebellar neuronal degeneration in repair-deficient Cockayne syndrome mice.

Authors:  R R Laposa; E J Huang; J E Cleaver
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 3.  Nucleotide excision repair deficient mouse models and neurological disease.

Authors:  Laura J Niedernhofer
Journal:  DNA Repair (Amst)       Date:  2008-02-12

4.  Cockayne syndrome B protects against methamphetamine-enhanced oxidative DNA damage in murine fetal brain and postnatal neurodevelopmental deficits.

Authors:  Gordon P McCallum; Andrea W Wong; Peter G Wells
Journal:  Antioxid Redox Signal       Date:  2011-01-05       Impact factor: 8.401

5.  Early postnatal ataxia and abnormal cerebellar development in mice lacking Xeroderma pigmentosum Group A and Cockayne syndrome Group B DNA repair genes.

Authors:  M Murai; Y Enokido; N Inamura; M Yoshino; Y Nakatsu; G T van der Horst; J H Hoeijmakers; K Tanaka; H Hatanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 6.  DNA repair deficiency in neurodegeneration.

Authors:  Dennis Kjølhede Jeppesen; Vilhelm A Bohr; Tinna Stevnsner
Journal:  Prog Neurobiol       Date:  2011-04-30       Impact factor: 11.685

Review 7.  Cockayne syndrome and xeroderma pigmentosum.

Authors:  I Rapin; Y Lindenbaum; D W Dickson; K H Kraemer; J H Robbins
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

Review 8.  Cockayne syndrome in adults: review with clinical and pathologic study of a new case.

Authors:  Isabelle Rapin; Karen Weidenheim; Yelena Lindenbaum; Pearl Rosenbaum; Saumil N Merchant; Sindu Krishna; Dennis W Dickson
Journal:  J Child Neurol       Date:  2006-11       Impact factor: 1.987

Review 9.  Tissue-specific accelerated aging in nucleotide excision repair deficiency.

Authors:  Laura J Niedernhofer
Journal:  Mech Ageing Dev       Date:  2008-05-01       Impact factor: 5.432

10.  Clinical implications of the basic defects in Cockayne syndrome and xeroderma pigmentosum and the DNA lesions responsible for cancer, neurodegeneration and aging.

Authors:  J E Cleaver; I Revet
Journal:  Mech Ageing Dev       Date:  2008-02-03       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.